¼¼°èÀÇ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼ : Á¦Ç° À¯Çüº°, Á¦Çüº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)
Montelukast Sodium Market Share, Size, Trends, Industry Analysis Report, By Product Type (Montelukast Sodium Amorphous and Montelukast Sodium Crystalline); By Dosage Form; By Application; By Region; Segment Forecast, 2024- 2032
»óǰÄÚµå
:
1463101
¸®¼Ä¡»ç
:
Polaris Market Research
¹ßÇàÀÏ
:
2024³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 118 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°èÀÇ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 7¾ï 7,378¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¼³¹®Á¶»ç º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀåÀº ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò ´öºÐ¿¡ ²ÙÁØÇÑ ¼ºÀåÀ» º¸¿©ÁÝ´Ï´Ù. ·ùÄÚÆ®¸®¿£ ¼ö¿ëü ±æÇ×Á¦ÀÎ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀº ÁַΠõ½Ä Áõ»óÀÇ °ü¸®¿Í ¿¹¹æ, ¾Ë·¹¸£±â¼º ºñ¿°ÀÇ Áõ»ó ¿ÏÈ¿¡ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ Áõ»ó¿¡ ´ëÇÑ È¿°ú´Â ¼¼°è ½ÃÀåÀÇ È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ õ½Ä°ú ¾Ë·¹¸£±â¼º ºñ¿°ÀÇ À¯º´·üÀÌ ¼¼°èÀûÀ¸·Î »ó½ÂÇϰí ÀÖ´Â °Íµµ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÇコÄɾ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í Áø´Ü ´É·ÂÀÌ Çâ»óµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ Áúº´À¸·Î Áø´Ü¹Þ´Â »ç¶÷ÀÌ ´Ã¾î³ª ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃßÁøÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ ¿ëµµ¸¦ È®´ëÇϱâ À§ÇØ Á¦¾àȸ»ç°¡ R&D Ȱµ¿¿¡ ÁÖ·ÂÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ Å« ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¿îµ¿ À¯¹ß¼º ±â°üÁö ¼öÃà ¹× ¸¸¼º Æó»ö¼º Æó Áúȯ(COPD)°ú °°Àº ´Ù¸¥ È£Èí±â ÁúȯÀÇ Ä¡·áÁ¦·Î¼ÀÇ ÀáÀç·ÂÀ» ޱ¸ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, ±× °á°ú ½ÃÀåÀÇ ÆøÀÌ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ ¾ÈÀü¼º°ú È¿´É ÇÁ·ÎÆÄÀÏÀ» ÅëÇØ ¼Ò¾Æ Áý´Ü¿¡¼ÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÌ ½ÃÀå È®´ë¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ Áö¿ª¿¡¼ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý Á¦Á¦¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ º¸±ÞÀ» ÃËÁøÇÏ°í ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ Á¦³×¸¯ ÀǾàǰÀÇ ÃâÇöµµ ƯÈ÷ Àú·ÅÇÑ °¡°Ý°ú ÀÔ¼ö ¿ëÀ̼ºÀÌ Áß¿äÇÑ °ü½É»çÀÎ ½ÅÈï±¹ ½ÃÀå¿¡¼ ½ÃÀå ħÅõ È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
Áö¿ªº° ºÐ¼®¿¡¼´Â ºÏ¹Ì°¡ ÇöÀç ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â ÁÖ·Î ÀÌ Áö¿ª¿¡¼ õ½Ä ¹× ¾Ë·¹¸£±â¼º ºñ¿°ÀÇ À¯º´·üÀÌ ³ô°í, È®¸³µÈ ÇコÄɾî ÀÎÇÁ¶óÀÇ Á¸Àç¿¡ ±ÍÂøµË´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È Å« ¼ºÀå ±âȸ¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·áºñ Áõ°¡, È£Èí±â Áúȯ¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡¿¡¼ ȯÀÚ Àα¸ È®´ë µîÀÇ ¿äÀÎÀÌ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ ºñÁ¤Áú ºÎ¹®Àº È£Èí±â ÁúȯÀÇ ¿¹¹æ¿¡ ³Î¸® »ç¿ëµÇ±â ¶§¹®¿¡ 2023³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Á¤Á¦ ºÎ¹®Àº 2023³â¿¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â ¿î¹ÝÇϱ⠽±°í, Á¤È®ÇÑ Åõ¿©°¡ °¡´ÉÇϸç, ¿À¿° °¡´É¼ºÀÌ ÀûÀº µî ¸¹Àº ÀÌÁ¡ÀÌ Àֱ⠶§¹®ÀÔ´Ï´Ù.
õ½Ä ºÐ¾ß´Â 2023³â¿¡ ½ÃÀåÀ» ¼±µµÇßÁö¸¸, ÀÌ´Â ¼¼°è õ½Ä ÀÌȯÀ² Áõ°¡¿Í ÀÌ¿ë °¡´ÉÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀÇ½Ä ¶§¹®ÀÔ´Ï´Ù.
È£Èí±â ÁúȯÀÇ À¯º´·ü »ó½Â°ú »õ·Î¿î ¿ëµµ¸¦ ¹ß°ßÇϱâ À§ÇÑ ¿¬±¸È°µ¿ÀÇ È°¼ºÈ·Î 2023³â ¼¼°è ½ÃÀåÀº ºÏ¹Ì°¡ ¿ìÀ§¸¦ Â÷Áö
ÁÖ¿ä ½ÃÀå ¼±¼ö´Â Sandoz International, Sun Pharmaceutical Industries, Merck, Cipla, Aurobindo Pharma µîÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ¼¼°è ½ÃÀå ÀλçÀÌÆ®
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ÀÀ¿ë ½º³À¼¦
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- °í·ÉÈ Àα¸ Áõ°¡°¡ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎ
- ½Ä½À°üÀÇ º¯È¿Í ±Þ¼ÓÇÑ µµ½ÃȰ¡ ½ÃÀå ¼ºÀåÀ» °¡¼Ó
- ¾ïÁ¦¿äÀΰú °úÁ¦
- ¸óÅ×·çÄ«½ºÆ®¿Í °ü·ÃµÈ ºÎÀÛ¿ë
- PESTEL ºÐ¼®
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀåÀÇ ÀÀ¿ë µ¿Çâ
- ¹ë·ùüÀÎ ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦5Àå Á¦Çüº° ¼¼°è ½ÃÀå
- ÁÖ¿ä Á¶»ç °á°ú
- ¼Ò°³
- Á¤Á¦
- ÀúÀÛ¼º Ÿºí·¿
- °æ±¸¿ë¾×
Á¦6Àå Á¦Ç° À¯Çüº° ¼¼°è ½ÃÀå
- ÁÖ¿ä Á¶»ç °á°ú
- ¼Ò°³
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ºñÁ¤Áú
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý °áÁ¤
Á¦7Àå ¿ëµµº° ¼¼°è ½ÃÀå
- ÁÖ¿ä Á¶»ç °á°ú
- ¼Ò°³
- õ½Ä
- ¾Ë·¹¸£±â¼º ºñ¿° µÎµå·¯±â
- ±âŸ
Á¦8Àå Áö¿ªº° ¼¼°è ½ÃÀå
- ÁÖ¿ä Á¶»ç °á°ú
- ¼Ò°³
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå Æò°¡, Áö¿ªº°(2019-2032³â)
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ºÏ¹Ì
- ºÏ¹Ì : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Çüº°(2019-2032³â)
- ºÏ¹Ì : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, ¿ëµµº°(2019-2032³â)
- ºÏ¹Ì : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Ç° À¯Çüº°(2019-2032³â)
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¹Ì±¹
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ij³ª´Ù
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - À¯·´
- À¯·´ : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Çüº°(2019-2032³â)
- À¯·´ : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, ¿ëµµº°(2019-2032³â)
- À¯·´ : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Ç° À¯Çüº°(2019-2032³â)
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¿µ±¹
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ÇÁ¶û½º
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - µ¶ÀÏ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ÀÌÅ»¸®¾Æ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ½ºÆäÀÎ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ³×´ú¶õµå
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ·¯½Ã¾Æ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Çüº°(2019-2032³â)
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, ¿ëµµº°(2019-2032³â)
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Ç° À¯Çüº°(2019-2032³â)
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - Áß±¹
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - Àεµ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¸»·¹À̽þÆ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ÀϺ»
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - Àεµ³×½Ã¾Æ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - Çѱ¹
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Çüº°(2019-2032³â)
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, ¿ëµµº°(2019-2032³â)
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Ç° À¯Çüº°(2019-2032³â)
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - UAE
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - À̽º¶ó¿¤
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ³²¾ÆÇÁ¸®Ä«
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä« : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Çüº°(2019-2032³â)
- ¶óƾ¾Æ¸Þ¸®Ä« : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, ¿ëµµº°(2019-2032³â)
- ¶óƾ¾Æ¸Þ¸®Ä« : ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå, Á¦Ç° À¯Çüº°(2019-2032³â)
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¸ß½ÃÄÚ
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ºê¶óÁú
- ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª
Á¦9Àå °æÀï ±¸µµ
- È®´ë ¹× Àμö ºÐ¼®
- ÆÄÆ®³Ê½Ê/Çù¾÷/°è¾à/°ø°³
Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Apotex Inc.(Canada)
- .Aurobindo Pharma Ltd.(India)
- Cipla Ltd.(India)
- Glenmark Pharmaceutical Ltd.(India)
- Jubilant Life Sciences Ltd.(India)
- Merck & Co. Inc.(US)
- Mylan NV(US)
- Sandoz International GmbH(Germany)
- Sun Pharmaceutical Industries Ltd.(India)
- Teva Pharmaceutical Industries Ltd.(Israel)
JHS
¿µ¹® ¸ñÂ÷
The global montelukast sodium market size is expected to reach USD 773.78 million by 2032, according to a new study by Polaris Market Research. The report "Montelukast Sodium Market Share, Size, Trends, Industry Analysis Report, By Product Type (Montelukast Sodium Amorphous and Montelukast Sodium Crystalline); By Dosage Form; By Application; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The Montelukast Sodium market is witnessing steady growth owing to several key factors driving its expansion. Montelukast Sodium, a leukotriene receptor antagonist, is primarily used to manage and prevent asthma symptoms and to relieve symptoms of allergic rhinitis. Its efficacy in treating these conditions has contributed significantly to the expansion of the global market. Additionally, the rise in the prevalence of asthma and allergic rhinitis cases worldwide has fueled the demand for Montelukast Sodium. As healthcare awareness continues to increase and diagnostic capabilities improve, more individuals are being diagnosed with these conditions, further boosting the market's growth.
Furthermore, the growing focus on research and development activities by pharmaceutical companies to expand the application of Montelukast Sodium is a significant driver of market growth. These efforts aim to explore its potential in treating other respiratory conditions, such as exercise-induced bronchoconstriction and chronic obstructive pulmonary disease (COPD), thus widening its market scope. Additionally, the increasing adoption of Montelukast Sodium in pediatric populations, owing to its safety and efficacy profiles, has further propelled market expansion.
Moreover, the market is witnessing favorable regulatory approvals for Montelukast Sodium formulations in various regions, which have facilitated its widespread availability and contributed to market growth. The emergence of generic versions of Montelukast Sodium has also played a crucial role in expanding market penetration, particularly in developing regions where affordability and accessibility are key concerns.
In terms of regional analysis, North America currently holds a significant share of the Montelukast Sodium market, primarily attributed to the high prevalence of asthma and allergic rhinitis in the region and the presence of established healthcare infrastructure. However, the Asia-Pacific region is anticipated to exhibit substantial growth opportunities during the forecast period. Factors such as the rising healthcare expenditure, increasing awareness about respiratory diseases, and the expanding patient population in countries like China and India are expected to drive market growth in this region.
Montelukast Sodium Market Report Highlights
Montelukast sodium amorphous segment accounted for largest share in 2023, owing to its widespread use to prevent respiratory diseases with greater efficacy
Tablets segment held the maximum share in 2023, that is attributed to its numerous benefits including easy transportation, accurate dosage, and low chance of contamination
Asthma segment led the market in 2023, due to growing incidences of asthma worldwide and awareness among people about the available treatment options of disease
North America dominated the global market in 2023, on account of rising prevalence of respiratory conditions and growing research activities to discover new uses
The key market players include Sandoz International, Sun Pharmaceutical Industries, Merck, Cipla, and Aurobindo Pharma
Polaris Market Research has segmented the montelukast sodium market report based on product type, dosage form, application, and region:
Montelukast Sodium, Product Type Outlook (Revenue - USD Million, 2023 - 2032)
- Montelukast Sodium Amorphous
- Montelukast Sodium Crystalline
Montelukast Sodium, Dosage Form Outlook (Revenue - USD Million, 2023 - 2032)
- Tablets
- Chewable Tablets
- Oral Solutions
Montelukast Sodium, Application Outlook (Revenue - USD Million, 2023 - 2032)
- Asthma
- Allergic Rhinitis Urticaria
- Others
Montelukast Sodium, Regional Outlook (Revenue - USD Million, 2023 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Montelukast Sodium Market Insights
- 4.1. Montelukast Sodium Market - Application Snapshot
- 4.2. Montelukast Sodium Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing geriatric population to drive market growth
- 4.2.1.2. Change in dietary habits and rapid urbanization to spur market growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Side effects associated with montelukast
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Montelukast Sodium Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Montelukast Sodium Market, by Dosage Form
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 5.3. Tablets
- 5.3.1. Global Montelukast Sodium Market, by Tablets, by Region, 2019-2032 (USD Million)
- 5.4. Chewable Tablets
- 5.4.1. Global Montelukast Sodium Market, by Chewable Tablets, by Region, 2019-2032 (USD Million)
- 5.5. Oral Solutions
- 5.5.1. Global Montelukast Sodium Market, by Oral Solutions, by Region, 2019-2032 (USD Million)
6. Global Montelukast Sodium Market, by Product Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 6.3. Montelukast Sodium Amorphous
- 6.3.1. Global Montelukast Sodium Market, by Montelukast Sodium Amorphous, by Region, 2019-2032 (USD Million)
- 6.4. Montelukast Sodium Crystalline
- 6.4.1. Global Montelukast Sodium Market, by Montelukast Sodium Crystalline, by Region, 2019-2032 (USD Million)
7. Global Montelukast Sodium Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 7.3. Asthma
- 7.3.1. Global Montelukast Sodium Market, by Asthma, By Region, 2019-2032 (USD Million)
- 7.4. Allergic Rhinitis Urticaria
- 7.4.1. Global Montelukast Sodium Market, by Allergic Rhinitis Urticaria, By Region, 2019-2032 (USD Million)
- 7.5. Others
- 7.5.1. Global Montelukast Sodium Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Montelukast Sodium Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Montelukast Sodium Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Montelukast Sodium Market - North America
- 8.3.1. North America: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.3.2. North America: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.3.3. North America: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.3.4. Montelukast Sodium Market - U.S.
- 8.3.4.1. U.S.: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.3.5. Montelukast Sodium Market - Canada
- 8.3.5.1. Canada: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4. Montelukast Sodium Market - Europe
- 8.4.1. Europe: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.2. Europe.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.3. Europe: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.4. Montelukast Sodium Market - UK
- 8.4.4.1. UK: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.4.3. UK: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.5. Montelukast Sodium Market - France
- 8.4.5.1. France: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.5.2. France.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.5.3. France: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.6. Montelukast Sodium Market - Germany
- 8.4.6.1. Germany: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.7. Montelukast Sodium Market - Italy
- 8.4.7.1. Italy: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.8. Montelukast Sodium Market - Spain
- 8.4.8.1. Spain: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.9. Montelukast Sodium Market - Netherlands
- 8.4.9.1. Netherlands: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.4.10. Montelukast Sodium Market - Russia
- 8.4.10.1. Russia: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5. Montelukast Sodium Market - Asia Pacific
- 8.5.1. Asia Pacific: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5.4. Montelukast Sodium Market - China
- 8.5.4.1. China: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.4.2. China.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.4.3. China: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5.5. Montelukast Sodium Market - India
- 8.5.5.1. India: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.5.2. India.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.5.3. India: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5.6. Montelukast Sodium Market - Malaysia
- 8.5.6.1. Malaysia: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5.7. Montelukast Sodium Market - Japan
- 8.5.7.1. Japan: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5.8. Montelukast Sodium Market - Indonesia
- 8.5.8.1. Indonesia: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.5.9. Montelukast Sodium Market - South Korea
- 8.5.9.1. South Korea: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.6. Montelukast Sodium Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.6.4. Montelukast Sodium Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.6.5. Montelukast Sodium Market - UAE
- 8.6.5.1. UAE: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.6.6. Montelukast Sodium Market - Israel
- 8.6.6.1. Israel: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.6.7. Montelukast Sodium Market - South Africa
- 8.6.7.1. South Africa: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.7. Montelukast Sodium Market - Latin America
- 8.7.1. Latin America: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.7.3. Latin America: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.7.4. Montelukast Sodium Market - Mexico
- 8.7.4.1. Mexico: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.7.5. Montelukast Sodium Market - Brazil
- 8.7.5.1. Brazil: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
- 8.7.6. Montelukast Sodium Market - Argentina
- 8.7.6.1. Argentina: Montelukast Sodium Market, by Dosage Form, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Montelukast Sodium Market, by Application, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Montelukast Sodium Market, by Product Type, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Apotex Inc. (Canada)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. .Aurobindo Pharma Ltd. (India)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Cipla Ltd. (India)
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Glenmark Pharmaceutical Ltd. (India)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Jubilant Life Sciences Ltd. (India)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Merck & Co. Inc. (US)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Mylan N.V. (US)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sandoz International GmbH (Germany)
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sun Pharmaceutical Industries Ltd. (India)
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Teva Pharmaceutical Industries Ltd. (Israel)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
°ü·ÃÀÚ·á